Archive: Company News
Company News: Aleva Neurotherapeutics Announces Promising Clinical Data on Directional Deep Brain Stimulation with directSTIM™
– Data Presented at the 2013 Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery (WSSFN) –
Tokyo, Japan, May 30, 2013 – Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, today announced interim clinical data of an interventional, intraoperative pilot study of its novel directSTIM™ electrode. Data were presented at the 2013 Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery (WSSFN) in Tokyo, Japan, on May 30.
In the ongoing pilot study, clinical investigators assessed the intraoperative clinical effect of directional stimulation using the directSTIM™ lead. It features two rings consisting of three independent electrodes each. The angular position of the electrodes allows stimulation at 0°, 120° and 240° directions. After assessment, directSTIM™ was removed and replaced by a classical, ring-shaped permanent DBS lead.
The data reported in Tokyo are based on 5 males with Parkinson Disease, which underwent Subthalamic Nucleus (STN) DBS, and 2 males with essential tremor, which underwent Ventral Intermediate Nucleus of the Thalamus (Vim) DBS. Directional stimulation was tested at the target determined for the permanent lead. The clinical investigators compared the therapeutic window (TW, defined as the electrical current threshold at which side effects occur minus the current threshold at which a significant therapeutic effect is observed) of directional and classical stimulation. Directional stimulation resulted in an improved therapeutic window in five of six patients (the ratio could not be measured in one of seven patients). No adverse event took place.
“This is a real breakthrough in the field of DBS. At present, DBS is carried out using ring-shaped electrodes,” said Claudio Pollo, MD, Head of Functional Neurosurgery at the University Hospital, Bern, Switzerland and Principal Investigator of the study. “This intraoperative study is the first to investigate the proof-of-concept of directional stimulation in humans. The increased therapeutic window demonstrated in the study suggests that directional stimulation is more selective for beneficial effects while avoiding side effects. Moreover, the observed side effects were consistent with what we expected given the anatomical structures surrounding the stimulated area.”
“We are very pleased with the data, as we have proof-of-concept in an intraoperative setting that directional stimulation is measurable and that it is different from classical stimulation,“ said Jean-Pierre Rosat, CEO of Aleva Neurotherapeutics. “This is very promising as it indicates that the effectiveness of DBS may be improved by our novel electrodes.”
Alain Dransart, Aleva’s Clinical and Regulatory Director, concluded: “We are delighted by the way the study is conducted and by the excellent collaboration with the investigators. The pilot study will be completed by the end of this year and we believe its results will pave the way for a future directSTIMTM chronic study.”
Company News: SUPPRESTEM Consortium Led by Merus Receives € 6 Million FP7 Grant from the European Union
– Development of Therapeutic Bispecific Antibodies (Biclonics™) Targeting Treatment-resistant Cancer Stem Cells Using Patient-Derived Organoid Screening Tools –
Utrecht, The Netherlands, May 27, 2013 – Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today announced that it has been granted funding from the European Union’s FP7 program. Merus is leading the SUPPRESSTEM consortium which was granted a total of about €6 million to develop novel antibody-based therapeutics targeting cancer stem cells for the treatment of colorectal cancer as well as patient-derived organoid-based screening tools to aid drug discovery. The consortium includes The Hubrecht Institute (The Netherlands), OcellO B.V. (The Netherlands), Fundacio Privada Institut de Recerca Biomedica (Spain), and The Wellcome Trust Sanger Institute (UK).
Specifically, the consortium is addressing mechanisms that lead to the development of treatment resistance and tumor escape in colon cancer, a problem that has hampered the development of efficient therapeutics in the past. Furthermore, it is pioneering the application of patient-derived tissue in drug discovery to address the high clinical failure rate in cancer drug research. It is hoped that the SUPPRESSTEM results will have broad application in cancer drug development.
In the SUPPRESSTEM consortium, Merus will develop Biclonics™ antibodies which will both modulate the Wnt pathway and address growth factor receptors to specifically inhibit cancer stem cells with minimal toxicity on healthy tissue. Functional screening of these stem cell-targeting bispecific antibodies for specific inhibitory activity and for selecting lead candidates will be done using organoids.
Company News: Curetis Raises EUR 12.5 Million in Series B Round Led by New Investor HBM Partners
– Co-investment of all current institutional investors as well as several private investors and management
– Company now has access to over EUR 20 million in cash for the next phase of commercial and operational growth
Curetis AG today announced the closing of a Series B financing round totaling EUR 12.5 million. The financing was led by HBM Partners, which has taken a EUR 6.0 million equity stake in Curetis. Dr. Alexander Asam of HBM will join Curetis’ supervisory board.
In addition, the company’s existing institutional investors aeris Capital, LSP Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD Venture and KfW have contributed a total of EUR 5.6 million to the round on a pro rata basis. Curetis’ management as well as several of the company’s founders, private investors and board members also co-invested.
Including the latest Series B financing, Curetis has raised a total of EUR 49.1 million in equity capital to date.
Curetis will use the proceeds for the next phase of commercial and operational growth, including a prospective, multi-center FDA registrational trial with 2,000 patients and the further expansion of the company’s commercial activities and team in Europe.
Curetis anticipates a phase of rapid market adoption in the DACH region (Germany, Austria, Switzerland) where more than 50 top tier hospitals have agreed to install Unyvero™ for local testing. The inclusion of Unyvero™ in an upcoming global Phase IIb trial by Sanofi Pasteur is expected to add further momentum to the market penetration of Unyvero™.
Moreover, the company expects to continue the rapid international expansion of its commercial distribution network across Europe and the Middle East, but also towards Asia, Latin America and, following FDA clearance, to the USA.
Further upcoming milestones include the market launch of a second Unyvero™ cartridge application (ITI) together with Heraeus Medical and clinical data from a global Phase III trial in community-acquired bacterial pneumonia conducted by Cempra Pharmaceuticals.
Company News: Curetis to Present Clinical Unyvero™ Data at ECCMID 2013 in Berlin
– Company to host medical symposium on molecular antibiotic resistance testing in standard care
Curetis AG today announced the presentation of top-line clinical data from various European cohorts and performance evaluation studies of the Unyvero™ System and the Unyvero™ P50 pneumonia cartridge at the European Conference of Clinical Microbiology and Infectious Diseases (ECCMID) 2013 in Berlin. Data from the analysis of more than 1,000 patient samples and case reports will be presented in the poster session “Molecular diagnosis of bacterial pneumonia” on Monday, April 29, from 12:30-1:30pm.*
As an ECCMID silver sponsor, Curetis will also host a medical symposium on Saturday, April 27 (1:30-3:30pm) in Hall B (P.32). The symposium entitled “Does molecular antibiotic resistance testing improve diagnostics and standard of care?” will be chaired by Professors Carl-Erik Nord and Christian G. Giske (both Stockholm/Sweden). Featured presentations will be “Genotypes and phenotypes of emerging resistance” (Prof. David Livermore, Norwich/UK) and “Correlation between genotypes and phenotypes: clinical implications” (Prof. Gian Maria Rossolini, Siena/Italy). The session will conclude with the discussion of case studies in pneumonia (Prof. Antonio Torres, Barcelona/Spain, Prof. Eiman Mokaddas, Kuwait) and implant & tissue infection (Prof. Andrej Trampuz, Berlin/Germany and Prof. Olivier Borens, Lausanne/Switzerland).
Curetis will be exhibiting its CE-marked Unyvero™ System at booth no. 323 in hall 15. Several international distribution partners of Curetis will also attend ECCMID.
_______________________________________
*Abstract Nr. 2360: M. Klein et al., First clinical validation of a rapid molecular test (Unyvero™ P50 Pneumonia Application) detecting microorganisms and antibiotic resistances in patients suspected with severe pneumonia.